Friday’s withdrawal of the Republican health care bill from Congress must have created considerable relief in many corners of the health care industry. Not only had Democrats and many moderate Republicans expressed concern over the bill’s potential consequences for patients, but interest groups lined up almost uniformly against the bill. The American Hospital Association, American Medical Association, AARP, and dozens of other groups representing hospitals, providers, and patients all opposed the bill.

Yet the pharmaceutical industry, and its lobbying group PhRMA in particular, were largely silent as the bill was being discussed, debated, and ultimately withdrawn. This silence is somewhat puzzling, in light of the significant negative impact the Republican bill would have had on the industry.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy